Scarica l'app Stockscreener
1.17
9.30%
-0.12
Dopo l'orario di chiusura:
1.18
0.01
+0.85%
Precedente Chiudi:
$1.29
Aprire:
$1.31
Volume 24 ore:
2.27M
Relative Volume:
2.10
Capitalizzazione di mercato:
$70.58M
Reddito:
-
Utile/perdita netta:
$-27.37M
Rapporto P/E:
-2.5703
EPS:
-0.4552
Flusso di cassa netto:
$-25.99M
1 W Prestazione:
-2.90%
1M Prestazione:
-21.48%
6M Prestazione:
-29.52%
1 anno Prestazione:
-78.01%
Intervallo 1D:
$1.15
$1.31
Intervallo di 1 settimana:
$1.15
$1.44
Portata 52W:
$1.07
$5.93
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Nome
Aldeyra Therapeutics Inc
Settore
Industria
Telefono
781-761-4904
Indirizzo
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.17 | 72.69M | 0 | -27.37M | -25.99M | -0.4552 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-04-03 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-04-02 | Ripresa | H.C. Wainwright | Buy |
| 2022-04-27 | Ripresa | H.C. Wainwright | Buy |
| 2021-02-08 | Iniziato | H.C. Wainwright | Buy |
| 2020-12-16 | Iniziato | Berenberg | Buy |
| 2020-10-30 | Iniziato | Jefferies | Buy |
| 2020-10-16 | Iniziato | BTIG Research | Buy |
| 2020-09-22 | Iniziato | Alliance Global Partners | Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Outperform |
| 2018-12-04 | Iniziato | Citigroup | Buy |
| 2018-09-26 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Iniziato | Janney | Buy |
| 2018-01-26 | Iniziato | Seaport Global Securities | Buy |
| 2016-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2016-07-01 | Iniziato | Stifel | Buy |
| 2015-07-01 | Iniziato | Canaccord Genuity | Buy |
| 2015-03-25 | Iniziato | Chardan Capital Markets | Buy |
| 2015-03-20 | Reiterato | H.C. Wainwright | Buy |
| 2014-11-18 | Iniziato | H.C. Wainwright | Buy |
| 2014-06-19 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Aldeyra Therapeutics Inc Borsa (ALDX) Ultime notizie
Aldeyra Therapeutics, Inc. (ALDX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Aldeyra Therapeutics Price Target Maintained With a $9.00/Share by BTIG - Moomoo
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect - ACCESS Newswire
H.C. Wainwright reiterates Neutral on Aldeyra stock at $2 target By Investing.com - Investing.com Canada
ALDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $2.00 - GuruFocus
HC Wainwright & Co. reiterates Neutral rating on Aldeyra Therapeutics, $2 price target - TradingView
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye DiseaseSlideshow (NASDAQ:ALDX) 2026-09-30 - Seeking Alpha
Aldeyra Therapeutics Stock Surges as It Files an FDA Dispute ResolutionAldeyra Therapeutics (NASDAQ:AL - Benzinga
ALDX Reiterated by BTIG -- Price Target Maintained at $9.00 - GuruFocus
Aldeyra to appeal FDA rejection of reproxalap as a treatment for dry eye disease - Ophthalmology Times
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease - Yahoo Finance
Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter - Yahoo Finance
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Zacks Investment Research
Form 8K Aldeyra Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Aldeyra to appeal FDA rejection of dry eye drug reproxalap By Investing.com - Investing.com South Africa
Aldeyra to appeal FDA rejection of dry eye drug reproxalap - Investing.com
Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease - TradingView
After three FDA denial letters, Aldeyra plans a formal challenge over its dry eye drug. - Stock Titan
Aldeyra Therapeutics to Host Regulatory Update Webcast - FinancialContent
Aldeyra Therapeutics Inc. (ALDX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Aldeyra Therapeutics Inc (ALDX) Stock Price Target & Forecast - TradingKey
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ALDX: Aldeyra Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - stocktwits.com
Aldeyra Therapeutics, Inc. (ALDX) Latest Stock News & Headlines - Yahoo Finance
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally? - TradingView
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-09-06 | Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALDX | Press Release - stockhouse.com
Aldeyra Therapeutics, Inc. (ALDX) Options Chain - Yahoo Finance
Here's Why You Should Add ARQT Stock to Your Portfolio Now - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Research Analysts Issue Forecasts for ALDX Q3 Earnings - MarketBeat
AQR Capital Management Expands Aldeyra Therapeutics (ALDX) Stake Despite Steep Stock Decline - GuruFocus
HC Wainwright Has Optimistic Outlook of ALDX FY2030 Earnings - MarketBeat
H.C. Wainwright Maintains Aldeyra Therapeutics(ALDX.US) With Hold Rating, Maintains Target Price $2 - Moomoo
Aldeyra Therapeutics (ALDX) Climbs 8.33% as Biotech Stock Approaches Resistance at $1.64Covered Call Trade - vinanet.vn
Aldeyra Therapeutics (NASDAQ:ALDX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
ALDX Q2 2026 Earnings: Narrower-Than-Expected Loss of $0.09 per Share Points to Cost DisciplineMid-Term Outlook - careplusvn.com
Aldeyra Therapeutics (ALDX): AQR Capital discloses 6.22% beneficial ownership stake - Stock Titan
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect - ACCESS Newswire
Aldeyra Therapeutics Inc (ALDX) Stock News Today - TradingKey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Reach Out - accessnewswire.com
ALDX Q1 2026 Earnings: Narrower-Than-Expected Loss of $0.06 per Share Amid Pipeline-Focused StrategyRevenue Warning Signal - dars.gov.et
Aldeyra Therapeutics (NASDAQ:ALDX) Announces Quarterly Earnings Results - marketbeat.com
Aldeyra Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aldeyra Therapeutics, Inc. Q2 2026: Net loss $5.45M, EPS $(0.09) — 10-Q Summary - TradingView
Aldeyra Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Aldeyra Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
Aldeyra Therapeutics Inc Azioni (ALDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aldeyra Therapeutics Inc Azioni (ALDX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DOUGLAS RICHARD | Director |
Mar 19 '26 |
Buy |
1.40 |
70,000 |
98,000 |
195,000 |
| Alfieri Michael | Principal Financial Officer |
Mar 18 '26 |
Buy |
1.42 |
5,000 |
7,100 |
7,500 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):